196 related articles for article (PubMed ID: 36551566)
1. Cellular and Molecular Effects of Eribulin in Preclinical Models of Hematologic Neoplasms.
Vicari HP; Lima K; Costa-Lotufo LV; Machado-Neto JA
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551566
[TBL] [Abstract][Full Text] [Related]
2. Integrating mechanisms of response and resistance against the tubulin binding agent Eribulin in preclinical models of osteosarcoma.
Sampson VB; Vetter NS; Zhang W; Patil PU; Mason RW; George E; Gorlick R; Kolb EA
Oncotarget; 2016 Dec; 7(52):86594-86607. PubMed ID: 27863409
[TBL] [Abstract][Full Text] [Related]
3. Multiple modes of action of eribulin mesylate: Emerging data and clinical implications.
Cortes J; Schöffski P; Littlefield BA
Cancer Treat Rev; 2018 Nov; 70():190-198. PubMed ID: 30243063
[TBL] [Abstract][Full Text] [Related]
4. PI3K inhibition enhances the anti-tumor effect of eribulin in triple negative breast cancer.
Rajput S; Guo Z; Li S; Ma CX
Oncotarget; 2019 Jun; 10(38):3667-3680. PubMed ID: 31217901
[TBL] [Abstract][Full Text] [Related]
5. Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer.
Scarpace SL
Clin Ther; 2012 Jul; 34(7):1467-73. PubMed ID: 22739019
[TBL] [Abstract][Full Text] [Related]
6. Eribulin Synergistically Increases Anti-Tumor Activity of an mTOR Inhibitor by Inhibiting pAKT/pS6K/pS6 in Triple Negative Breast Cancer.
Wen W; Marcinkowski E; Luyimbazi D; Luu T; Xing Q; Yan J; Wang Y; Wu J; Guo Y; Tully D; Han ES; Yost SE; Yuan Y; Yim JH
Cells; 2019 Aug; 8(9):. PubMed ID: 31480338
[TBL] [Abstract][Full Text] [Related]
7. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.
Yoshida T; Ozawa Y; Kimura T; Sato Y; Kuznetsov G; Xu S; Uesugi M; Agoulnik S; Taylor N; Funahashi Y; Matsui J
Br J Cancer; 2014 Mar; 110(6):1497-505. PubMed ID: 24569463
[TBL] [Abstract][Full Text] [Related]
8. The Microtubule Destabilizer Eribulin Synergizes with STING Agonists to Promote Antitumor Efficacy in Triple-Negative Breast Cancer Models.
Takahashi-Ruiz L; Fermaintt CS; Wilkinson NJ; Chan PYW; Mooberry SL; Risinger AL
Cancers (Basel); 2022 Dec; 14(23):. PubMed ID: 36497445
[TBL] [Abstract][Full Text] [Related]
9. Combination of eribulin plus AKT inhibitor evokes synergistic cytotoxicity in soft tissue sarcoma cells.
Hayasaka N; Takada K; Nakamura H; Arihara Y; Kawano Y; Osuga T; Murase K; Kikuchi S; Iyama S; Emori M; Sugita S; Hasegawa T; Takasawa A; Miyanishi K; Kobune M; Kato J
Sci Rep; 2019 Apr; 9(1):5759. PubMed ID: 30962488
[TBL] [Abstract][Full Text] [Related]
10. Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions.
Towle MJ; Salvato KA; Wels BF; Aalfs KK; Zheng W; Seletsky BM; Zhu X; Lewis BM; Kishi Y; Yu MJ; Littlefield BA
Cancer Res; 2011 Jan; 71(2):496-505. PubMed ID: 21127197
[TBL] [Abstract][Full Text] [Related]
11. Microtubule-targeting anticancer drug eribulin induces drug efflux transporter P-glycoprotein.
Nabekura T; Kawasaki T; Jimura M; Mizuno K; Uwai Y
Biochem Biophys Rep; 2020 Mar; 21():100727. PubMed ID: 31993509
[TBL] [Abstract][Full Text] [Related]
12. Single-cell pharmacokinetic imaging reveals a therapeutic strategy to overcome drug resistance to the microtubule inhibitor eribulin.
Laughney AM; Kim E; Sprachman MM; Miller MA; Kohler RH; Yang KS; Orth JD; Mitchison TJ; Weissleder R
Sci Transl Med; 2014 Nov; 6(261):261ra152. PubMed ID: 25378644
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacometric analyses of eribulin in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes.
Majid O; Gupta A; Reyderman L; Olivo M; Hussein Z
J Clin Pharmacol; 2014 Oct; 54(10):1134-43. PubMed ID: 24771603
[TBL] [Abstract][Full Text] [Related]
14. Effects of Paclitaxel and Eribulin in Mouse Sciatic Nerve: A Microtubule-Based Rationale for the Differential Induction of Chemotherapy-Induced Peripheral Neuropathy.
Benbow SJ; Cook BM; Reifert J; Wozniak KM; Slusher BS; Littlefield BA; Wilson L; Jordan MA; Feinstein SC
Neurotox Res; 2016 Feb; 29(2):299-313. PubMed ID: 26659667
[TBL] [Abstract][Full Text] [Related]
15. Antitumor and anticancer stem cell activities of eribulin mesylate and antiestrogens in breast cancer cells.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Moriya T
Breast Cancer; 2016 May; 23(3):425-36. PubMed ID: 25552385
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase.
Okouneva T; Azarenko O; Wilson L; Littlefield BA; Jordan MA
Mol Cancer Ther; 2008 Jul; 7(7):2003-11. PubMed ID: 18645010
[TBL] [Abstract][Full Text] [Related]
17. Stathmin expression alters the antiproliferative effect of eribulin in leiomyosarcoma cells.
Azumi M; Yoshie M; Nakachi N; Tsuru A; Kusama K; Tamura K
J Pharmacol Sci; 2022 Dec; 150(4):259-266. PubMed ID: 36344048
[TBL] [Abstract][Full Text] [Related]
18. Eribulin: a novel cytotoxic chemotherapy agent.
Preston JN; Trivedi MV
Ann Pharmacother; 2012 Jun; 46(6):802-11. PubMed ID: 22619477
[TBL] [Abstract][Full Text] [Related]
19. Eribulin synergizes with Polo-like kinase 1 inhibitors to induce apoptosis in rhabdomyosarcoma.
Stehle A; Hugle M; Fulda S
Cancer Lett; 2015 Aug; 365(1):37-46. PubMed ID: 25917079
[TBL] [Abstract][Full Text] [Related]
20. Multifarious targets beyond microtubules-role of eribulin in cancer therapy.
Seshadri P; Deb B; Kumar P
Front Biosci (Schol Ed); 2021 Dec; 13(2):157-172. PubMed ID: 34879468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
